TRA 2°P-TIMI 50

The study was designed to determine whether SCH 530348, when added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) in patients with a known history of atherosclerosis, will yield additional benefit over the existing standard of care without SCH 530348 in preventing heart attack and stroke. The study was also designed to assess risk of bleeding with SCH 530348 added to the standard of care versus the standard of care alone.

PRESENTATIONS

PAR-1 Antagonist (ESC 2015)

Scientific Update: Latest Results from TRA 2°P-TIMI 50 (Webcast)

Diabetes (Circulation 2015)
Approval Population (TCT 2014)
Polyvascular Disease (ACC 2013)
Stent Thombosis (AHA 2013)
Peripheral Artery Disease (AHA – ESS 2012)
Stroke (AHA 2012)
TRA2P-TIMI 50 CLI Cart Analysis (Bonaca AHA 2019)

PUBLICATIONS

Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2 degrees P-TIMI 50 trial

Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 degrees P-TIMI 50 Trial

External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction

Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function

High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 degrees P – TIMI 50 Trial

Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 degrees P-TIMI 50 trial

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50

Efficacy And Safety Of Vorapaxar For Secondary Prevention In Older Patients: Observations From TRA 2°P-TIMI 50

Bleeding In Stable Patients With Atherosclerotic Disease: Insights From TRA2°P- TIMI 50 Trial

Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 degrees P-TIMI 50)

Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2 degrees P-TIMI 50 Trial

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2 degrees P-TIMI 50)

Efficacy and safety of vorapaxar as approved for clinical use in the United States

Vorapaxar And Acute Limb Ischemia: Insights From The Thrombin Receptor Antagonist In Secondary Prevention Of Atherothrombotic Ischemic Events-TIMI 50 Trial

Statin Intensity And Outcome In Patients With Peripheral Artery Disease: Insights From The TRA2P-TIMI 50 Trial

Vorapaxar And Peripheral Revascularization: Insights Fom The TRA2P-TIMI 50 Trial

High-sensitivity Troponin I in Stable Patients With Atherosclerotic Disease in the TRA2°P- TIMI 50 Trial

Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2 degrees P-TIMI 50

PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease

Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2 degrees P-TIMI 50 Trial

New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2 degrees P-TIMI 50 Trial

Efficacy and safety of vorapaxar in patients with prior ischemic stroke

Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA 2P-TIMI 50

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial

Vorapaxar in the secondary prevention of atherothrombotic events

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

 

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close